 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
 | |
| Formerly | Isis Pharmaceuticals, Inc. |
|---|---|
| Company type | Public |
| |
| Industry | Biotechnology |
| Founded | 1989 |
| Founder | Stanley T. Crooke |
| Headquarters | Carlsbad, California, U.S. |
Key people | Brett P. Monia (CEO)[1] Elizabeth L. Hougen (CFO)[2] Joseph Loscalzo (chairman of the board)[3] |
| Products | nusinersen, inotersen, volanesorsen, plazomicin, mipomersen |
| Revenue |  US$587 million (2022) |
| US$−270 million (2022) | |
| Total assets | US$2.53 billion (2022) |
| Total equity | US$573 million (2022) |
Number of employees | 796 (December 2022) |
| Website | ionispharma |
| Footnotes / references [4] | |
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen), and has four drugs in pivotal studies: tominersen for Huntington's disease (together with Roche), tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.[4]
The company was named Isis Pharmaceuticals until December 2015.[5]
- ^ "Brett P Monia Chief Executive Officer/Co-Founder, Ionis Pharmaceuticals Inc". www.bloomberg.com. Retrieved 20 May 2022.
- ^ "Elizabeth L. Hougen Chief Financial Officer & Executive VP-Finance, Ionis Pharmaceuticals, Inc". www.wsj.com. Retrieved 20 May 2022.
- ^ "Ionis announces changes to its board of directors at annual meeting of stockholders". www.prnewswire.com (Press release). Retrieved 20 May 2022.
- ^ a b "Ionis Pharmaceuticals, Inc. 2022 Form 10-K Annual Report". U.S. Securities and Exchange Commission. February 22, 2023.
- ^ Fikes, Bradley (December 18, 2015). "From Isis Pharma to Ionis". The San Diego Union-Tribune.